T. Rowe Price Investment Management, Inc. Zentalis Pharmaceuticals, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $163 Billion
- Q1 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 3,319,086 shares of ZNTL stock, worth $12 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
3,319,086
Previous 2,341,783
41.73%
Holding current value
$12 Million
Previous $35.5 Million
47.44%
% of portfolio
0.03%
Previous 0.02%
Shares
7 transactions
Others Institutions Holding ZNTL
# of Institutions
142Shares Held
76.3MCall Options Held
68.2KPut Options Held
2.3K-
Matrix Capital Management Company, LP Waltham, MA14MShares$50.5 Million2.04% of portfolio
-
Eventide Asset Management, LLC Boston, MA11.6MShares$41.9 Million2.94% of portfolio
-
Black Rock Inc. New York, NY4.65MShares$16.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.4MShares$15.9 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.85MShares$13.9 Million0.01% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $206M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...